Sunday, July 6, 2025 7/6/2025

Systems Modeling of Tumor Heterogeneity and Therapy Response in Colorectal Cancer

Award Number: R01CA208179
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2017
PERIOD OF PERFORMANCE END DATE: 05/31/2023

Group Awards By:

View Award Description

Systems Modeling of Tumor Heterogeneity and Therapy Response in Colorectal Cancer - PROJECT SUMMARY/ABSTRACT Colorectal cancer (CRC) has one of the highest worldwide incidence (>1.3 million new cases) and mortality rates (~610,000 deaths annually). Genotoxic chemotherapy in stage II and III confers minimal treatment benefit (im- proved survival in 3-4% stage II patients and 15-20% patients in stage III), and predictive markers for therapy response are lacking. CRC patients would strongly benefit from novel prognostic and predictive biomarkers that identify patients who will not benefit from 5-FU-based chemotherapy, redirecting them towards targeted or novel interventions and intensified disease monitoring. One of the challenges in implementing such a biomarker approach is that CRC is a highly heterogeneous disease, with evidence for multiple subtypes emerging. The pur- ported causes of chemotherapy resistance are complex and multi-factorial, including dysfunctional apoptosis pathways, immune cell cytotoxicity (in turn, negatively affecting apoptosis and reducing immune-competency) and presence of cancer stem cells (and expression of multi-drug resistance proteins). The numbers, spatial dis- tribution and pathway status of these cells in the tumor and stromal area (and their heterogeneity) is an import- ant consideration, but the significance is not understood. The central hypothesis under investigation in this pro- posal is that modeling of apoptosis pathways at a cellular level and integration with tumor heterogeneity mark- ers in stage II and III CRC patient samples will better predict chemotherapy response, compared to standard biomarkers and treatment algorithms. While the immediate application would be for stage II patients, the re- sults will provide much needed new mechanistic insights into stage III outcomes and diagnostic opportunities for new therapies. We will use a novel single cell imaging technology to profile up to 50 proteins in a single tis- sue micro array (TMA) sections and quantify cellular and spatial distribution in tumor and stromal regions. in >1500 stage II and III CRC patients. These proteins will represent the apoptosis pathway, tumor microenviron- ment, stem cells, stroma and epithelial cells and be quantified at single cell level. Established models will be used to convert single cell apoptosis data into apoptosis competency scores. Heterogeneity in cellular apoptosis will be correlated with recurrence risk in treated and untreated patients. Tumor microenviroment measures (stroma, immune, endothelial), stem cells and available molecular subtype data will be combined with apoptosis scores to further elucidate therapy response. We will validate significant predictive biomarkers in a randomized controlled trial with chemotherapy treated and untreated patients. Finally, in a subset of patients with available cell lines, we will experimentally investigate mechanisms of drug resistance and test whether novel apoptosis- inducing therapies could potentially provide an alternative to chemotherapy. Predictive biomarkers in CRC could potentially save hundreds of thousands of patients per year from treatments with limited benefit and pro- vide oncologists with greater ability to direct patients towards other therapies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	GENERAL ELECTRIC COMPANY	1 RESEARCH CIR	NISKAYUNA	NY	12309	SCHENECTADY	USA	Cancer Detection and Diagnosis Research	000	5	1/29/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $645,756 )
2021	2021	GENERAL ELECTRIC COMPANY	1 RESEARCH CIR	NISKAYUNA	NY	12309	SCHENECTADY	USA	Cancer Detection and Diagnosis Research	000	5	5/21/2021	NON-COMPETING CONTINUATION	$645,756
														Subtotal = $645,756

Issue Date FY: 2020 ( Subtotal = $556,323 )
2020	2020	GENERAL ELECTRIC COMPANY	1 RESEARCH CIR	NISKAYUNA	NY	12309	SCHENECTADY	USA	Cancer Detection and Diagnosis Research	000	4	5/29/2020	NON-COMPETING CONTINUATION	$556,323
														Subtotal = $556,323

Issue Date FY: 2019 ( Subtotal = $709,442 )
2019	2019	GENERAL ELECTRIC COMPANY	1 RESEARCH CIR	NISKAYUNA	NY	12309	SCHENECTADY	USA	Cancer Detection and Diagnosis Research	000	3	4/25/2019	NON-COMPETING CONTINUATION	$709,442
														Subtotal = $709,442

Issue Date FY: 2018 ( Subtotal = $765,244 )
2018	2018	GENERAL ELECTRIC COMPANY	1 RESEARCH CIR	NISKAYUNA	NY	12309	SCHENECTADY	USA	Cancer Detection and Diagnosis Research	000	2	5/21/2018	NON-COMPETING CONTINUATION	$765,244
														Subtotal = $765,244

Issue Date FY: 2017 ( Subtotal = $853,654 )
2017	2017	GENERAL ELECTRIC COMPANY	1 RESEARCH CIR	NISKAYUNA	NY	12309	SCHENECTADY	USA	Cancer Detection and Diagnosis Research	000	1	5/26/2017	NEW	$853,654
														Subtotal = $853,654

Grand Total All Awards = $3,530,419

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Systems Modeling of Tumor Heterogeneity and Therapy Response in Colorectal Cancer

Award Number: R01CA208179

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2017

PERIOD OF PERFORMANCE END DATE: 05/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer